Tedesco, K L <br/><br/>
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Mar 2004 
 - 1071-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2004.10.046  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Docetaxel<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>Middle Aged<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Receptor, ErbB-3--antagonists & inhibitors<br/>Survival Analysis<br/>Taxoids--administration & dosage<br/>Trastuzumab<br/>United States<br/>Up-Regulation